Idor­si­a's Fab­ry dis­ease pro­gram flops a PhI­II study, leav­ing its fu­ture un­clear

A top pro­gram for Swiss biotech Idor­sia faces a murky fu­ture af­ter flunk­ing a Phase III test.

Idorisa’s drug can­di­date for Fab­ry dis­ease, known as lucera­s­tat, did not achieve the pri­ma­ry end­point in a 118-pa­tient piv­otal study, the biotech an­nounced Mon­day morn­ing. The com­pa­ny, re­leas­ing no da­ta, says it plans to wait for in­ter­im re­sults from an open-la­bel ex­ten­sion be­fore mak­ing a de­ci­sion about the pro­gram, but ad­mits that could take up to four years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER